Landscape Capital Management L.L.C. Has $865,000 Stock Position in Exelixis, Inc. $EXEL

Key Points

• Landscape Capital Management L.L.C. increased its stake in Exelixis, Inc. by 286.1%, holding 23,427 shares valued at $865,000 as of the latest SEC filing.
• Several institutional investors made significant changes to their positions in EXEL, contributing to a combined ownership of 85.27% in the company's stock.
• Exelixis recently reported earnings of $0.75 per share, which exceeded analysts' estimates, although their quarterly revenue of $568.26 million fell short of projections.

Landscape Capital Management L.L.C. grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 286.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,427 shares of the biotechnology company's stock after acquiring an additional 17,360 shares during the quarter. Landscape Capital Management L.L.C.'s holdings in Exelixis were worth $865,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in EXEL. Stifel Financial Corp acquired a new stake in shares of Exelixis in the 4th quarter valued at approximately $1,669,000. Northern Trust Corp boosted its holdings in shares of Exelixis by 25.7% in the 4th quarter. Northern Trust Corp now owns 2,478,460 shares of the biotechnology company's stock valued at $82,533,000 after buying an additional 506,539 shares during the last quarter. Comerica Bank boosted its holdings in shares of Exelixis by 0.6% in the 4th quarter. Comerica Bank now owns 87,681 shares of the biotechnology company's stock valued at $2,920,000 after buying an additional 544 shares during the last quarter. AXA S.A. boosted its holdings in shares of Exelixis by 578.3% in the 4th quarter. AXA S.A. now owns 89,130 shares of the biotechnology company's stock valued at $2,968,000 after buying an additional 75,989 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Exelixis by 226.9% in the 4th quarter. BNP Paribas Financial Markets now owns 430,457 shares of the biotechnology company's stock valued at $14,334,000 after buying an additional 298,798 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several recent analyst reports. Royal Bank Of Canada cut their price objective on Exelixis from $50.00 to $45.00 and set a "sector perform" rating for the company in a report on Tuesday, July 29th. Morgan Stanley dropped their price target on Exelixis from $48.00 to $46.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 29th. Bank of America increased their price target on Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. Benchmark restated a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Finally, Jefferies Financial Group set a $50.00 price target on Exelixis and gave the company a "buy" rating in a research note on Tuesday, June 24th. Thirteen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $44.06.

Insider Buying and Selling at Exelixis

In other news, Director Sue Gail Eckhardt sold 18,838 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $42.74, for a total transaction of $805,136.12. Following the sale, the director directly owned 21,380 shares of the company's stock, valued at approximately $913,781.20. This represents a 46.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jack L. Wyszomierski sold 7,535 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total value of $324,683.15. Following the sale, the director directly owned 358,882 shares in the company, valued at approximately $15,464,225.38. This trade represents a 2.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.82% of the stock is owned by company insiders.

Exelixis Price Performance

EXEL stock opened at $37.42 on Friday. The stock has a market capitalization of $10.07 billion, a price-to-earnings ratio of 17.99, a PEG ratio of 0.77 and a beta of 0.29. The business's fifty day moving average price is $41.26 and its two-hundred day moving average price is $39.49. Exelixis, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.12. The firm had revenue of $568.26 million for the quarter, compared to analysts' expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company's quarterly revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. Research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.